Compare Summit Therapeutics Inc (SMMT) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs VICI Properties Inc — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while VICI Properties Inc trades at $26.7 (market cap $29.55B). The key difference: VICI Properties Inc is far larger — about 2.8× Summit Therapeutics Inc's market cap, and VICI Properties Inc pays a 6.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VICI | |
|---|---|---|
Market Cap | $10.48B | $29.55B |
Sector | Health | Real Estate |
52-Week High | $29.32 | $33.93 |
52-Week Low | $13.05 | $25.94 |
Enterprise Value | $9.90B | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
VICI Properties trades at $26.83, down slightly (-0.15%) on the day. The stock shows strong fundamentals with a P/E of 9.19, net income margin of 76.83%, and consistent earnings beats in recent quarters. Technical indicators are mixed with an overall bullish signal but bearish moving averages. Recent news highlights institutional activity with CalPERS reducing its stake while Aviance Capital Partners initiated a new position.
VICI offers a compelling investment case with attractive valuation metrics, robust profitability, and a 6.62% dividend yield. However, risks include tenant concentration with Caesars/MGM accounting for 70% of rent and potential lease uncertainties from recent buyout discussions. Analyst consensus remains strongly bullish with a $29.00 price target suggesting 8% upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
